All the news articles and press releases in one place.

Date / Time Source Company Sector Market Cap Announcement
10Dec18 06:03 GNW Roche Holding Ltd Dividend Right Cert. Various Various New member proposed for election to Roche Board of Directors
10Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Changes to the Roche Corporate Executive Committee
07Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
05Dec18 13:15 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
05Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
04Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
03Dec18 18:30 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
03Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
21Nov18 19:15 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
13Nov18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
01Nov18 16:35 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
01Nov18 06:03 GNW Roche Holding Ltd Dividend Right Cert. Various Various Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
01Nov18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
29Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various New STAIRWAY study data shows potential for extended durability with Roche's faricimab in neovascular age-related macular degeneration (nAMD)
24Oct18 18:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
22Oct18 15:30 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
22Oct18 08:15 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone
21Oct18 10:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
20Oct18 15:30 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
17Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche reports very strong growth in the first nine months of 2018
15Oct18 06:05 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
15Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
10Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis
09Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
04Oct18 17:40 GNW Roche Holding Ltd Dividend Right Cert. Various Various FDA approves Roche's Hemlibra for haemophilia A without factor VIII inhibitors
04Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
03Oct18 12:30 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
02Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
25Sep18 14:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
24Sep18 14:50 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
24Sep18 14:45 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
24Sep18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
18Sep18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases
13Sep18 10:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running
06Sep18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)
30Aug18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Positive phase III results for Roche's Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
28Aug18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Changes to the Roche Corporate Executive Committee
20Aug18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
03Aug18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington's disease
31Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche Purchases Shares in Tender Offer for FMI
26Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche reports very strong performance in the first half of 2018
23Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche receives CE Mark for its Accu-Chek Solo micropump system
20Jul18 06:03 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche to present new data demonstrating the breadth and depth of its Alzheimer's programme at the upcoming Alzheimer's Association International Conference
20Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease
19Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
18Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
17Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu
02Jul18 16:35 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
02Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Phase III IMpassion130 study showed Roche's Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
25Jun18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche's TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy
22Jun18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Changes to the Roche Enlarged Corporate Executive Committee
19Jun18 06:00 GNW Roche Holding Ltd Dividend Right Cert. Various Various Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
15Jun18 07:30 GNW Roche Holding Ltd Dividend Right Cert. Various Various New long-term data confirm Roche's Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Date / Time Source Company % Chg
10Dec18 06:03 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
New member proposed for election to Roche Board of Directors
10Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Changes to the Roche Corporate Executive Committee
07Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
05Dec18 13:15 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
05Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
04Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
03Dec18 18:30 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
03Dec18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
21Nov18 19:15 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
13Nov18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
01Nov18 16:35 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
01Nov18 06:03 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
01Nov18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
29Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
New STAIRWAY study data shows potential for extended durability with Roche's faricimab in neovascular age-related macular degeneration (nAMD)
24Oct18 18:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
22Oct18 15:30 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
22Oct18 08:15 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone
21Oct18 10:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
20Oct18 15:30 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
17Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche reports very strong growth in the first nine months of 2018
15Oct18 06:05 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
15Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
10Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis
09Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
04Oct18 17:40 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
FDA approves Roche's Hemlibra for haemophilia A without factor VIII inhibitors
04Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
03Oct18 12:30 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
02Oct18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
25Sep18 14:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
24Sep18 14:50 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
24Sep18 14:45 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
24Sep18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
18Sep18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases
13Sep18 10:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running
06Sep18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)
30Aug18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Positive phase III results for Roche's Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
28Aug18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Changes to the Roche Corporate Executive Committee
20Aug18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
03Aug18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington's disease
31Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche Purchases Shares in Tender Offer for FMI
26Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche reports very strong performance in the first half of 2018
23Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche receives CE Mark for its Accu-Chek Solo micropump system
20Jul18 06:03 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche to present new data demonstrating the breadth and depth of its Alzheimer's programme at the upcoming Alzheimer's Association International Conference
20Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease
19Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
18Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
17Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu
02Jul18 16:35 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
02Jul18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Phase III IMpassion130 study showed Roche's Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
25Jun18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche's TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy
22Jun18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Changes to the Roche Enlarged Corporate Executive Committee
19Jun18 06:00 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
15Jun18 07:30 GNW Roche Holding Ltd Dividend Right Cert. 1.10%
New long-term data confirm Roche's Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Date / Time Company % Chg
10Dec18 06:03 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG RTS,ROG MIL,ROG SWX,ROGZ BATSLON 1.10%
New member proposed for election to Roche Board of Directors
10Dec18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG RTS,ROG MIL,ROG SWX,ROGZ BATSLON 1.10%
Changes to the Roche Corporate Executive Committee
07Dec18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG MIL,ROG SWX,ROG MIL,ROGZ BATSLON 1.10%
FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
05Dec18 13:15 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG MIL,ROG SWX,ROG MIL,ROGZ BATSLON 1.10%
Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
05Dec18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG MIL,ROG SWX,ROG MIL,ROGZ BATSLON 1.10%
FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
04Dec18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG SWX,ROG MIL,ROG RTS,ROGZ BATSLON 1.10%
New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
03Dec18 18:30 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG SWX,ROG MIL,ROG RTS,ROGZ BATSLON 1.10%
Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
03Dec18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG SWX,ROG MIL,ROG RTS,ROGZ BATSLON 1.10%
Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
21Nov18 19:15 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG MIL,ROG SWX,ROG MIL,ROGZ BATSLON 1.10%
Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
13Nov18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG MIL,ROG SWX,ROG MIL,ROGZ BATSLON 1.10%
FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
01Nov18 16:35 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG SWX,ROG MIL,ROG RTS,ROGZ BATSLON 1.10%
Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
01Nov18 06:03 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG MIL,ROG RTS,ROG MIL,ROGZ BATSLON 1.10%
Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
01Nov18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG MIL,ROG RTS,ROG MIL,ROGZ BATSLON 1.10%
Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
29Oct18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG MIL,ROG SWX,ROG MIL,ROGZ BATSLON 1.10%
New STAIRWAY study data shows potential for extended durability with Roche's faricimab in neovascular age-related macular degeneration (nAMD)
24Oct18 18:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG MIL,ROG RTS,ROG MIL,ROGZ BATSLON 1.10%
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
22Oct18 15:30 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG MIL,ROG RTS,ROG MIL,ROGZ BATSLON 1.10%
Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
22Oct18 08:15 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG SWX,ROG MIL,ROG RTS,ROGZ BATSLON 1.10%
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone
21Oct18 10:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG MIL,ROG SWX,ROG MIL,ROGZ BATSLON 1.10%
Roche's investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
20Oct18 15:30 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG RTS,ROG MIL,ROG SWX,ROGZ BATSLON 1.10%
Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
17Oct18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG MIL,ROG SWX,ROG MIL,ROGZ BATSLON 1.10%
Roche reports very strong growth in the first nine months of 2018
15Oct18 06:05 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG RTS,ROG MIL,ROG SWX,ROGZ BATSLON 1.10%
Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
15Oct18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG MIL,ROG SWX,ROG MIL,ROG RTS,ROGZ BATSLON 1.10%
Roche's Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
10Oct18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG MIL,ROG SWX,ROG MIL,ROGZ BATSLON 1.10%
OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis
09Oct18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
04Oct18 17:40 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
FDA approves Roche's Hemlibra for haemophilia A without factor VIII inhibitors
04Oct18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
03Oct18 12:30 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
02Oct18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
25Sep18 14:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Roche's Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
24Sep18 14:50 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
24Sep18 14:45 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
24Sep18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
18Sep18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Roche's NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases
13Sep18 10:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Roche ranked the most sustainable healthcare company in the Dow Jones Sustainability Indices for the tenth year running
06Sep18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)
30Aug18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Positive phase III results for Roche's Hemlibra for haemophilia A without factor VIII inhibitors published in New England Journal of Medicine
28Aug18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Changes to the Roche Corporate Executive Committee
20Aug18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer
03Aug18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington's disease
31Jul18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Roche Purchases Shares in Tender Offer for FMI
26Jul18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Roche reports very strong performance in the first half of 2018
23Jul18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Roche receives CE Mark for its Accu-Chek Solo micropump system
20Jul18 06:03 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Roche to present new data demonstrating the breadth and depth of its Alzheimer's programme at the upcoming Alzheimer's Association International Conference
20Jul18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease
19Jul18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Roche's Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
18Jul18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
17Jul18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu
02Jul18 16:35 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
02Jul18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Phase III IMpassion130 study showed Roche's Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
25Jun18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
Roche's TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy
22Jun18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Changes to the Roche Enlarged Corporate Executive Committee
19Jun18 06:00 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG RTS,ROG SWX,ROGZ BATSLON 1.10%
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
15Jun18 07:30 RHO5 XETRA,RHO6 XETRA,RO SWX,ROG SWX,ROG RTS,ROGZ BATSLON 1.10%
New long-term data confirm Roche's Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan